Golden State Wealth Management LLC Makes New $38,000 Investment in GSK plc (NYSE:GSK)

Golden State Wealth Management LLC purchased a new stake in GSK plc (NYSE:GSK) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 1,137 shares of the pharmaceutical company’s stock, valued at approximately $38,000.

Several other large investors have also recently made changes to their positions in the stock. Eastern Bank purchased a new position in GSK in the third quarter valued at about $26,000. Sunbelt Securities Inc. boosted its holdings in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. Crews Bank & Trust purchased a new position in shares of GSK in the 4th quarter worth approximately $26,000. Concord Wealth Partners grew its position in shares of GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Finally, ST Germain D J Co. Inc. raised its stake in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

Shares of GSK opened at $36.07 on Wednesday. The stock has a 50-day moving average of $34.29 and a two-hundred day moving average of $37.53. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.53 and a current ratio of 0.78. The stock has a market cap of $74.75 billion, a P/E ratio of 22.68, a P/E/G ratio of 1.42 and a beta of 0.64. GSK plc has a one year low of $31.72 and a one year high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, research analysts predict that GSK plc will post 4.07 EPS for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.36%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is presently 93.08%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GSK. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Six analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.